No Data
Astrazeneca (AZN.US) and Merck (MRK.US) jointly announced the positive top-line results of the KOMET phase 3 clinical trial.
Today, Astrazeneca (AZN.US) and Merck (MRK.US) jointly announced the positive top-line results of the phase 3 KOMET clinical trial.
Dow's 300-Point Fall Led By Losses In Shares Of Amgen, 3M
Argus Cuts Price Target on Merck to $125 From $140
Merck, AstraZeneca Report Positive Data for Koselugo in Adults
Daiwa Downgrades Merck & Co(MRK.US) to Hold Rating
Tuesday Market Finally Slows Down, Takes a Post Veterans Day Breather | Live Stock